Monoclonal antibody-induced cytokine-release syndrome
暂无分享,去创建一个
[1] Jeffrey W. Clark,et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, The oncologist.
[2] M. Friedrich. Cancer Drug Target , 2009 .
[3] M. Hashizume,et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. , 2008, Biological and Pharmaceutical Bulletin.
[4] K. Papadakis,et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. , 2008, Clinical immunology.
[5] John J. Young,et al. Abciximab: a review and update for clinicians , 2008, Expert review of cardiovascular therapy.
[6] D. Nixon,et al. Nine‐color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[7] D. Rondelli,et al. Enhancement of T cell activation by immobilized hu5C8 (anti‐CD40L) monoclonal antibody , 2008, European journal of haematology.
[8] A. Flügel,et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. , 2008, The Journal of clinical investigation.
[9] Quynh-Thu Le,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.
[10] P. Reichardt,et al. Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies , 2008, PloS one.
[11] C. Rocha-Lima,et al. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. , 2008, The oncologist.
[12] T. Robak. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. , 2008, Current cancer drug targets.
[13] R. Jankowitz,et al. Anaphylaxis After Administration of Ibritumomab Tiuxetan for Follicular Non-Hodgkin Lymphoma , 2008, Clinical nuclear medicine.
[14] M. Clatworthy,et al. Subcutaneous Administration of Alemtuzumab in Simultaneous Pancreas-Kidney Transplantation , 2007, Transplantation.
[15] D. Metcalfe,et al. The mast cell and allergic diseases: role in pathogenesis and implications for therapy , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[16] C. Wagner,et al. Simultaneous Detection of Eight Analytes in Human Serum by Two Commercially Available Platforms for Multiplex Cytokine Analysis , 2007, Clinical and Vaccine Immunology.
[17] John D Lambris,et al. Complement-targeted therapeutics , 2007, Nature Biotechnology.
[18] M. Regueiro,et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. , 2007, Gastroenterology.
[19] S. Breslin. Cytokine-release syndrome: overview and nursing implications. , 2007, Clinical journal of oncology nursing.
[20] J. Shupe,et al. Depletion of B Cells in Murine Lupus: Efficacy and Resistance1 , 2007, The Journal of Immunology.
[21] T. Crombet,et al. Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab , 2007, Cancer biology & therapy.
[22] M. Wadhwa,et al. “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.
[23] M. Pescovitz,et al. A Phase I/II Randomized Open‐Label Multicenter Trial of Efalizumab, a Humanized Anti‐CD11a, Anti‐LFA‐1 in Renal Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] J. Weber. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.
[25] B. Bonavida,et al. ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’ , 2007, Oncogene.
[26] P. Keegan,et al. FDA drug approval summary: panitumumab (Vectibix). , 2007, The oncologist.
[27] K. Price,et al. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. , 2007, Allergy and asthma proceedings.
[28] N. Sachdeva,et al. Cytokine quantitation: technologies and applications. , 2007, Frontiers in bioscience : a journal and virtual library.
[29] J. Araujo,et al. Pro‐ and Anti‐Inflammatory Cytokines Produced by Human Monocytes Challenged In Vitro with Paracoccidioides brasiliensis , 2007, Microbiology and immunology.
[30] B. Melichar,et al. Successful management of infusion reaction accompanying the start of cetuximab therapy , 2007, Supportive Care in Cancer.
[31] K. Flaherty,et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Ian M. Adcock,et al. Regulation of Th2 Cytokine Genes by p38 MAPK-Mediated Phosphorylation of GATA-31 , 2007, The Journal of Immunology.
[33] Ying Tang,et al. Monoclonal Antibody Clearance , 2007, Journal of Biological Chemistry.
[34] G. Gonzalez-Stawinski,et al. Rituximab as monotherapy for elicited xenoreactive antibody responses. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[35] K. Hardinger,et al. Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation , 2006, Pharmacotherapy.
[36] C. Chiu,et al. Successful treatment of elderly advanced lymphomatoid granulomatosis with rituximab‐CVP combination therapy , 2006, European journal of haematology.
[37] G. Marti,et al. Rituximab Induces an Interferon Gene Expression Signature in Patients with CLL. , 2006 .
[38] S. Krishnaswamy,et al. Ordered Cleavage of Prothrombin by Prothrombinase Results from Constrained Binding and Preferential Active Site Engagement by One of the Two Cleavage Sites in Prothrombin. , 2006 .
[39] M. Caligiuri,et al. A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities. , 2006 .
[40] M. Sculpher,et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. , 2006, Health technology assessment.
[41] R. Goiriz,et al. Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma. , 2006, Archives of dermatology.
[42] F. Scinicariello,et al. IgG Fc Receptor III Homologues in Nonhuman Primate Species: Genetic Characterization and Ligand Interactions12 , 2006, The Journal of Immunology.
[43] Yi Guan,et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.
[44] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.
[45] W. Pichler. Adverse side‐effects to biological agents , 2006, Allergy.
[46] M. Beyer,et al. Regulatory T cells in cancer. , 2006, Blood.
[47] S. Krause,et al. Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum , 2006, Journal of immunotherapy.
[48] F. Farzaneh,et al. The strange case of TGN1412 , 2006, Cancer Immunology, Immunotherapy.
[49] C. Love,et al. Imaging of infection and inflammation with 99mTc-Fanolesomab. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[50] A. Varki,et al. Loss of Siglec expression on T lymphocytes during human evolution , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[51] P. Rutgeerts,et al. Emerging Biological Treatments in Inflammatory Bowel Diseases , 2006, Digestive Diseases.
[52] P. Kufer,et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2006, Cancer Immunology, Immunotherapy.
[53] F. Rojo,et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer , 2006, British Journal of Cancer.
[54] H. Gaines,et al. Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. , 2006, Cytokine.
[55] J. Pons,et al. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma , 2006, Leukemia & lymphoma.
[56] K. Rai,et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M. Hallek,et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] M. Lapeyre-Mestre,et al. [Cardiac effects of cytokines produced after rituximab infusion]. , 2005, Bulletin du cancer.
[59] G. Weiner,et al. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. , 2005, Journal of immunological methods.
[60] A. Funk,et al. Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. , 2005, Comparative medicine.
[61] K. Haas,et al. The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice1 , 2005, The Journal of Immunology.
[62] D. M. Lyons,et al. Mutations in squirrel monkey glucocorticoid receptor impair nuclear translocation , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[63] G. Meno-Tetang,et al. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. , 2005, Basic & clinical pharmacology & toxicology.
[64] M. Linenberger,et al. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance , 2005, Leukemia.
[65] J. Armitage,et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Michel Theron,et al. An interferon‐γ‐related cytokine storm in SARS patients† , 2004, Journal of medical virology.
[67] Ajit Varki,et al. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Buckner,et al. Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies , 2004, Journal of immunotherapy.
[69] S. Mahdavifar,et al. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. , 2004, Journal of immunological methods.
[70] N. Fineberg,et al. Rituximab, Anti‐CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T‐Cell Responses , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[71] B. Nakken,et al. Apoptotic Effect of Rituximab on Peripheral Blood B Cells in Rheumatoid Arthritis , 2004, Scandinavian journal of immunology.
[72] O. Ramilo,et al. Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection , 2004, The Pediatric infectious disease journal.
[73] F. Marincola,et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration , 2004, Journal of Translational Medicine.
[74] R. Webster,et al. H5N1 influenza: a protean pandemic threat. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[75] M. Harris. Monoclonal antibodies as therapeutic agents for cancer. , 2004, The Lancet. Oncology.
[76] J. Bakker,et al. CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)* , 2004, Critical care medicine.
[77] J. Abrahamsson,et al. The paediatric cytarabine syndrome can be viewed as a drug‐induced cytokine release syndrome , 2004, British journal of haematology.
[78] S. Hart,et al. Immune Complexes Bind Preferentially to FcγRIIA (CD32) on Apoptotic Neutrophils, Leading to Augmented Phagocytosis by Macrophages and Release of Proinflammatory Cytokines1 , 2004, The Journal of Immunology.
[79] A. Falus,et al. Changing paradigm through a genome-based approach to clinical and basic immunology , 2004, Journal of Translational Medicine.
[80] L. Håkansson,et al. Cytokine production in peripheral blood cells during and outside the pollen season in birch‐allergic patients and non‐allergic controls , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[81] G. Hale,et al. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. , 2003, Rheumatology.
[82] R. Pierson,et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. , 2003, Transplant immunology.
[83] A. Schuerwegh,et al. Comparison of intracellular cytokine production with extracellular cytokine levels using two flow cytometric techniques , 2003, Cytometry. Part B, Clinical cytometry.
[84] P. Szlosarek,et al. Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .
[85] E. Haddad,et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab , 2003, Transplantation.
[86] J. Flynn,et al. Non‐cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients , 2003, Pediatric transplantation.
[87] Mamoru Ito,et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. , 2003, Blood.
[88] J. Bluestone,et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala) , 2003 .
[89] Barbara Foster,et al. Detection of Intracellular Cytokines by Flow Cytometry , 2002, Current protocols in immunology.
[90] J. Rak,et al. Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody , 2002, International journal of cancer.
[91] A. Kingsnorth,et al. Cytokine storm in acute pancreatitis. , 2002, Journal of hepato-biliary-pancreatic surgery.
[92] C. Gray,et al. The ELISPOT Assay: An Easily Transferable Method for Measuring Cellular Responses and Identifying T Cell Epitopes , 2002, Clinical chemistry and laboratory medicine.
[93] Joy A. Cavagnaro,et al. Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.
[94] B. Vincenzi,et al. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. , 2002, Journal of biological regulators and homeostatic agents.
[95] D. Palisaitis,et al. Potential Anaphylactic Shock with Abciximab Readministration , 2002, Pharmacotherapy.
[96] Yuni Fang,et al. Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines , 2002, Cancer Immunology, Immunotherapy.
[97] Michael Weisman,et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. , 2002, The Journal of rheumatology.
[98] Hong Wang,et al. In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells , 2002, Leukemia & lymphoma.
[99] R. Ober,et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.
[100] J. Baars,et al. Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.
[101] M. Keating,et al. Alemtuzumab: a novel monoclonal antibody , 2001, Expert opinion on biological therapy.
[102] X. Zheng,et al. Critical Role of Kupffer Cell-Derived IL-10 for Host Defense in Septic Peritonitis1 , 2001, The Journal of Immunology.
[103] C. Kallenberg,et al. Inflammation in autoimmunity: receptors for IgG revisited. , 2001, Trends in immunology.
[104] J. Pribble,et al. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis , 2001, Journal of endotoxin research.
[105] Y. Malykh,et al. N-Glycolylneuraminic acid in human tumours. , 2001, Biochimie.
[106] M. Grever,et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] M. Zembala,et al. Three-Color Flow Cytometry Detection of Intracellular Cytokines in Peripheral Blood Mononuclear Cells: Comparative Analysis of Phorbol Myristate Acetate-Ionomycin and Phytohemagglutinin Stimulation , 2001, Clinical Diagnostic Laboratory Immunology.
[108] A. Órfão,et al. Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and incubation periods. , 2001, Cytometry.
[109] R W Sweet,et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. , 2001, Clinical immunology.
[110] J. Barry,et al. PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1 , 2000, Transplantation.
[111] T. Gooley,et al. Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells1 , 2000, The Journal of Immunology.
[112] H. Biersack,et al. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[113] A. West,et al. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). , 2000, Biochemistry.
[114] T. Raju,et al. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.
[115] L. Presta,et al. EFFECTS OF HUMANIZED MONOCLONAL ANTIBODY TO RHESUS CD11a IN RHESUS MONKEY CARDIAC ALLOGRAFT RECIPIENTS12 , 2000 .
[116] J. Squifflet,et al. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322. , 2000, Transplantation.
[117] A. Badger,et al. Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies , 2000, Human & experimental toxicology.
[118] B. Dörken,et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. , 2000, Blood.
[119] P. Parren,et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. , 2000, Cellular immunology.
[120] L. Rink,et al. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. , 2000, Journal of immunological methods.
[121] J. Phillips,et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. , 1999, Transplantation.
[122] F. Zuckermann. Extrathymic CD4/CD8 double positive T cells. , 1999, Veterinary immunology and immunopathology.
[123] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .
[124] J. Moran,et al. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. , 1999, Transplantation.
[125] A. Kung,et al. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. , 1999, Clinical immunology.
[126] L. Koh,et al. Re-evaluation of benefits of BRCA1/2 testing. , 1999 .
[127] S. Asano,et al. The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. , 1999, Blood.
[128] M. Wener,et al. Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy. , 1998, Transplantation.
[129] H. Link. The cytokine storm in multiple sclerosis , 1998, Multiple sclerosis.
[130] I. T. Ten Berge,et al. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. , 1997, Transplantation.
[131] K. Laupland,et al. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. , 1997, The Journal of clinical investigation.
[132] C. Anasetti,et al. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. , 1997, Journal of immunology.
[133] P. Weiden,et al. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. , 1997, Clinical nuclear medicine.
[134] R. Kryscio,et al. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. , 1997, Transplantation.
[135] J. Leonard,et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. , 1997, Clinical immunology and immunopathology.
[136] J. Mwenda,et al. Analysis of primate major histocompatibility complex (MHC)-DQA1 locus by PCR-single strand conformation polymorphism (SSCP). , 1997, Cellular and molecular biology.
[137] R. Lutter,et al. Immunocytochemical and flow cytofluorimetric detection of intracellular IL-4, IL-5 and IFN-gamma: applications using blood- and airway-derived cells. , 1997, Journal of immunological methods.
[138] S. Hauser,et al. Characterization of the TCRB chain repertoire in the New World monkey Callithrix jacchus. , 1997, Journal of immunology.
[139] C. Jacobs,et al. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). , 1997, Transplantation.
[140] A. Compston,et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. , 1996, The Journal of clinical investigation.
[141] R. Zietse,et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. , 1996, Transplantation.
[142] C. Marsh,et al. The pathogenesis of sepsis. Factors that modulate the response to gram-negative bacterial infection. , 1996, Clinics in chest medicine.
[143] E. Vasquez,et al. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients. , 1996, Clinical transplantation.
[144] M. Isturiz,et al. Anti‐Oxidants Inhibit the Enhancement of the Immune Response Caused by Oil Adjuvants , 1996, Scandinavian journal of immunology.
[145] G. Danovitch,et al. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study. , 1996, Transplantation.
[146] A. Compston,et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. , 1996, Brain : a journal of neurology.
[147] A. Cosimi,et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. , 1996, Transplantation.
[148] D. Norman. Mechanisms of Action and Overview of OKT3 , 1995, Therapeutic drug monitoring.
[149] J. Isaacs,et al. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. , 1995, Therapeutic immunology.
[150] Y. Kobayashi,et al. Comparison of reactivity of monoclonal antibody (3F2) to trimeric tumor necrosis factor (TNF-alpha) with that to monomeric TNF-alpha. , 1995, Journal of biochemistry.
[151] M. Gately,et al. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). , 1994, Laboratory investigation; a journal of technical methods and pathology.
[152] I. T. Ten Berge,et al. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. , 1994, Kidney international.
[153] L. Chatenoud,et al. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. , 1994, Therapeutic immunology.
[154] I. T. Ten Berge,et al. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. , 1994, The Journal of clinical investigation.
[155] D. Kohan,et al. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. , 1994, Transplantation.
[156] F. Villinger,et al. TH1/TH2 subset analysis. I. Establishment of criteria for subset identification in PBMC samples from nonhuman primates , 1994, Journal of medical primatology.
[157] K. Heeg,et al. Superantigen mediated shock: a cytokine release syndrome. , 1993, Immunobiology.
[158] A. Billiau,et al. Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels , 1993, European journal of immunology.
[159] P. D. De Mulder,et al. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2. , 1993, Journal of the National Cancer Institute.
[160] J. Bromberg,et al. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. , 1993, Transplantation.
[161] D. Jeyarajah,et al. General aspects of cytokine-release syndrome: timing and incidence of symptoms. , 1993, Transplantation proceedings.
[162] S. D. Gorman,et al. The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties , 1993, European journal of immunology.
[163] C. Ferran,et al. EVIDENCE THAT ANTIHUMAN TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY PREVENTS OKT3‐INDUCED ACUTE SYNDROME , 1992, Transplantation.
[164] K. Stuhlmeier,et al. Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment , 1992, Journal of Clinical Immunology.
[165] D. Remick,et al. Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever , 1992, The Journal of experimental medicine.
[166] P. Parren,et al. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. , 1992, Journal of immunology.
[167] G. Szücs,et al. Binding and endocytosis of erythrocytes sensitized with rabbit IgG via Fc gamma receptors of human monocytes. , 1991, Immunology.
[168] J. Bluestone,et al. Inter‐mouse strain differences in the in vivo anti‐CD3 induced cytokine release , 1991, Clinical and experimental immunology.
[169] P. Vereerstraeten,et al. EVIDENCE THAT PENTOXIFYLLINE REDUCES ANTI‐CD3 MONOCLONAL ANTIBODY‐INDUCED CYTOKINE RELEASE SYNDROME , 1991, Transplantation.
[170] R. Bone,et al. The pathogenesis of sepsis. , 1991, Annals of internal medicine.
[171] Z. Ba,et al. The Complex Pattern of Cytokines in Sepsis Association Between Prostaglandins, Cachectin, and Interleukins , 1991, Annals of surgery.
[172] E. Chen,et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[173] Donald E. Mosier,et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency , 1988, Nature.
[174] C. Melief,et al. Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies. , 1987, Journal of immunology.
[175] A. Freedman,et al. Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of the role of autocrine effects on B-cell proliferation and of T-cell help in B-cell differentiation. , 1986, Cellular immunology.
[176] N. Dunlap,et al. Analysis of the monocyte Fc receptors and antibody-mediated cellular interactions required for the induction of T cell proliferation by anti-T3 antibodies. , 1985, Journal of immunology.
[177] K. Kano,et al. Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues. , 1979, Journal of immunology.
[178] H. Lowman,et al. Therapeutic anti-VEGF antibodies. , 2008, Handbook of experimental pharmacology.
[179] B. Combe,et al. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. , 2008, Clinical and experimental rheumatology.
[180] J. Ravetch,et al. Analyzing antibody-Fc-receptor interactions. , 2008, Methods in molecular biology.
[181] Mario Castro,et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. , 2008, The Journal of allergy and clinical immunology.
[182] Quynh-Thu Le,et al. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose , 2008 .
[183] L. Camacho. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. , 2008, Expert opinion on investigational drugs.
[184] J. Ravetch,et al. Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.
[185] A. Hagenbeek,et al. The therapeutic use of rituximab in non-Hodgkin's lymphoma. , 2007, European journal of haematology. Supplementum.
[186] K. Seeger,et al. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature. , 2006, Haematologica.
[187] K. Tada,et al. Severe infusion reaction induced by trastuzumab: A case report , 2003, Breast cancer.
[188] A. Swiatecka-Urban. Anti-Interleukin-2 Receptor Antibodies for the Prevention of Rejection in Pediatric Renal Transplant Patients , 2003, Paediatric drugs.
[189] 平松 英文. Complete reconstitution of human lymphocytes from cord blood CD34[+] cells using the NOD/SCID/γc null mice model , 2003 .
[190] M. Angelopoulou,et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders , 2001, Medical oncology.
[191] J. Leonard,et al. Immunotherapy of Non-Hodgkin's lymphomas. , 2001, Hematology. American Society of Hematology. Education Program.
[192] V. Diehl,et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study , 2001, Annals of Hematology.
[193] J. Rosenberg,et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. , 2001, The Journal of rheumatology.
[194] C. Dinarello,et al. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. , 1998, International reviews of immunology.
[195] G. Hale,et al. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. , 1994, Journal of hematotherapy.
[196] James D. Green,et al. Comparative Pathology of Recombinant Murine Interferon-γ in Mice and Recombinant Human Interferon-γ in Cynomolgus Monkeys , 1993 .
[197] E. Coligan. Current protocols in immunology , 1991 .
[198] Y. Nemerson,et al. Tissue factor revisited. , 1982, Progress in hemostasis and thrombosis.